Does Dr. ADNAN ELGHEZEWI have financial conflicts of interest?

Dr. ADNAN ELGHEZEWI (MD) has received a total of $1,491 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,491 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ADNAN ELGHEZEWI?

According to CMS Open Payments data, Dr. ADNAN ELGHEZEWI received funding from ABBVIE ($769), BOSTON SCIENTIFIC CORPORATION ($164), and TAKEDA PHARMACEUTICALS U.S.A ($151).

Does Dr. ADNAN ELGHEZEWI receive research grants or speaking fees?

Dr. ADNAN ELGHEZEWI has received $1,491 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ADNAN ELGHEZEWI

MDReal-Time Hydrated

Specialty: Internal Medicine, Gastroenterology

Practice Location: HUNTINGTON, WV 25705

NPI Number: 1407295959

LIFETIME INDUSTRY VALUE

$1,491

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ELGHEZEWI is a verified Internal Medicine, Gastroenterology practitioner based in HUNTINGTON, WV.

Between 2021 and 2025, Dr. ELGHEZEWI had an overall industry promotional and research financial footprint of $1,491 as recorded in the federal CMS Open Payments database.

$1,491 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ELGHEZEWI's primary funding source is ABBVIE, which accounts for $769 (representing 51.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ABBVIE

Rank 1

$769

51.6%

BOSTON SCIENTIFIC CORPORATION

Rank 2

$164

11%

TAKEDA PHARMACEUTICALS U.S.A

Rank 3

$151

10.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.